Limits...
Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution.

Li R, Li H, Yan W, Yang P, Bao Z, Zhang C, Jiang T, You Y - Oncotarget (2015)

Bottom Line: Mutations in isocitrate dehydrogenase-1 (IDH1) were found to be highly concentrated in the Proneural subtypes.In addition, patients with sGBM were 10 years younger on average than those with pGBM, and exhibited clinical features of shorter overall survival and frontal lobe tumor location tendency.Overall, these results reveal the intrinsic distinction between pGBM and sGBM, and provide insight into the genetic and clinical attributes of GBM.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

ABSTRACT
Glioblastoma multiforme (GBM) is classified into primary (pGBM) or secondary (sGBM) based on clinical progression. However, there are some limits to this classification for insight into genetically and clinically distinction between pGBM and sGBM. The aim of this study is to characterize pGBM and sGBM associating with differential molecular subtype distribution. Whole transcriptome sequencing data was used to assess the distribution of molecular subtypes and genetic alterations in 88 pGBM and 34 sGBM in a Chinese population-based cohort, and the biological progression and prognostic impact were analyzed by combining clinical information. Forty-one percentage of pGBM were designated as Mesenchymal subtype, while only 15% were the Proneural subtype. However, sGBM displayed the opposite ratio of Mesenchymal (15%) and Proneural (44%) subtypes. Mutations in isocitrate dehydrogenase-1 (IDH1) were found to be highly concentrated in the Proneural subtypes. In addition, patients with sGBM were 10 years younger on average than those with pGBM, and exhibited clinical features of shorter overall survival and frontal lobe tumor location tendency. Furthermore, in sGBM, gene sets related to malignant progression were found to be enriched. Overall, these results reveal the intrinsic distinction between pGBM and sGBM, and provide insight into the genetic and clinical attributes of GBM.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier analysis of overall survivals of patients with GBM(A) Overall survival of patients with pGBM and sGBM; (B) Overall survivals of patients with or without IDH1 mutation in pGBM and sGBM; (C) Overall survivals of patients with Proneural, Neural, Classical and Mesenchymal subtypes.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4466687&req=5

Figure 3: Kaplan–Meier analysis of overall survivals of patients with GBM(A) Overall survival of patients with pGBM and sGBM; (B) Overall survivals of patients with or without IDH1 mutation in pGBM and sGBM; (C) Overall survivals of patients with Proneural, Neural, Classical and Mesenchymal subtypes.

Mentions: The median overall survival of all patients with pGBM after diagnosis was 381 days, whereas the median overall survival was 284 days in patients with sGBM (Figure 3A). As shown in (Figure 3B), patients carrying the IDH1 mutation experienced an improved prognosis (1074 days for pGBM and 346 days for sGBM) compared with patients who did not have such a mutation (372 days for pGBM and 256 days for sGBM). When this analysis was combined with molecular subtypes, patients with Neural subtype pGBM exhibited the longest overall survival, followed by patients with Proneural subtype pGBM, with 970 days of median overall survival. Patients with Mesenchymal and Proneural subtypes of sGBM resulted in the worst clinical outcome, with survival of 236 and 231 days, respectively (Figure 3C).


Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution.

Li R, Li H, Yan W, Yang P, Bao Z, Zhang C, Jiang T, You Y - Oncotarget (2015)

Kaplan–Meier analysis of overall survivals of patients with GBM(A) Overall survival of patients with pGBM and sGBM; (B) Overall survivals of patients with or without IDH1 mutation in pGBM and sGBM; (C) Overall survivals of patients with Proneural, Neural, Classical and Mesenchymal subtypes.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4466687&req=5

Figure 3: Kaplan–Meier analysis of overall survivals of patients with GBM(A) Overall survival of patients with pGBM and sGBM; (B) Overall survivals of patients with or without IDH1 mutation in pGBM and sGBM; (C) Overall survivals of patients with Proneural, Neural, Classical and Mesenchymal subtypes.
Mentions: The median overall survival of all patients with pGBM after diagnosis was 381 days, whereas the median overall survival was 284 days in patients with sGBM (Figure 3A). As shown in (Figure 3B), patients carrying the IDH1 mutation experienced an improved prognosis (1074 days for pGBM and 346 days for sGBM) compared with patients who did not have such a mutation (372 days for pGBM and 256 days for sGBM). When this analysis was combined with molecular subtypes, patients with Neural subtype pGBM exhibited the longest overall survival, followed by patients with Proneural subtype pGBM, with 970 days of median overall survival. Patients with Mesenchymal and Proneural subtypes of sGBM resulted in the worst clinical outcome, with survival of 236 and 231 days, respectively (Figure 3C).

Bottom Line: Mutations in isocitrate dehydrogenase-1 (IDH1) were found to be highly concentrated in the Proneural subtypes.In addition, patients with sGBM were 10 years younger on average than those with pGBM, and exhibited clinical features of shorter overall survival and frontal lobe tumor location tendency.Overall, these results reveal the intrinsic distinction between pGBM and sGBM, and provide insight into the genetic and clinical attributes of GBM.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

ABSTRACT
Glioblastoma multiforme (GBM) is classified into primary (pGBM) or secondary (sGBM) based on clinical progression. However, there are some limits to this classification for insight into genetically and clinically distinction between pGBM and sGBM. The aim of this study is to characterize pGBM and sGBM associating with differential molecular subtype distribution. Whole transcriptome sequencing data was used to assess the distribution of molecular subtypes and genetic alterations in 88 pGBM and 34 sGBM in a Chinese population-based cohort, and the biological progression and prognostic impact were analyzed by combining clinical information. Forty-one percentage of pGBM were designated as Mesenchymal subtype, while only 15% were the Proneural subtype. However, sGBM displayed the opposite ratio of Mesenchymal (15%) and Proneural (44%) subtypes. Mutations in isocitrate dehydrogenase-1 (IDH1) were found to be highly concentrated in the Proneural subtypes. In addition, patients with sGBM were 10 years younger on average than those with pGBM, and exhibited clinical features of shorter overall survival and frontal lobe tumor location tendency. Furthermore, in sGBM, gene sets related to malignant progression were found to be enriched. Overall, these results reveal the intrinsic distinction between pGBM and sGBM, and provide insight into the genetic and clinical attributes of GBM.

Show MeSH
Related in: MedlinePlus